Genflow Biosciences PLC: Directorate Change Announcement

## Genflow Biosciences Taps Experienced Biotech Leader Gad Berdugo as Chairman Amidst Strategic Expansion

**LONDON, UK – January 19, 2026** – Genflow Biosciences Plc, a European biotechnology firm focused on gene therapies for age-related diseases, has announced a significant leadership transition with the immediate appointment of Gad Berdugo as Independent Non-Executive Chairman. This strategic move signals Genflow’s intent to accelerate its research and development pipeline and bolster its corporate presence, particularly within the U.S. market.

Mr. Berdugo brings a wealth of experience cultivated over three decades in the biotechnology sector. His expertise encompasses corporate development, U.S. capital markets, and crucially, the intricate field of RNA-lipid nanoparticle (LNP) therapeutics. Currently serving as Managing Partner of Explorium Capital LLC, a U.S.-based advisory firm specializing in the biotechnology landscape, Mr. Berdugo’s track record includes leadership roles in scaling both private and public development-stage companies. His prior experience includes co-founding EpiVax Oncology and serving as Chief Business Officer for notable entities such as Editas Medicine and Nutcracker Therapeutics, demonstrating a deep understanding of strategic partnerships, capital acquisition, and operational growth.

The company highlighted that Mr. Berdugo’s extensive background in RNA-based therapeutics, including LNP delivery, development, and manufacturing, will be instrumental in guiding Genflow’s scientific platform. His appointment is expected to support the evaluation of novel delivery technologies and the exploration of next-generation therapeutic approaches, a critical aspect for any company aiming to make significant inroads in the gene therapy space. Furthermore, his leadership is anticipated to enhance Genflow’s engagement within the United States, a key market for biopharmaceutical innovation and investment.

Tamara Joseph will continue her role on the Board of Directors, ensuring a seamless transition and upholding robust governance standards. Her continued presence provides institutional memory and continuity as the company embarks on this new phase.

Management has indicated that key data readouts are anticipated in 2026, a timeline that positions Mr. Berdugo’s leadership to directly influence the interpretation and strategic deployment of emerging scientific findings. This forward-looking outlook suggests a focused approach on advancing Genflow’s lead programs, which aim to combat age-related diseases and promote healthier longevity.

While Mr. Berdugo’s extensive experience in corporate development and capital markets is expected to invigorate Genflow’s strategic direction and potential for U.S. market access, it is noted that he does not currently hold any shares in the company. This may present an interesting dynamic as the company seeks to align leadership incentives with shareholder value creation.

Dr. Eric Leire, CEO of Genflow, expressed enthusiasm for the appointment, stating, “We are delighted to welcome Mr. Berdugo as Independent Non-Executive Chairman. His expertise in strategy, partnerships, and financing, as well as his deep experience with RNA-LNP technologies, will be instrumental as we accelerate our programs and expand our global reach. We are equally pleased that Mrs. Tamara Joseph will continue her service on the Board, contributing her invaluable leadership, legal, and governance expertise.”

Mr. Berdugo commented on his new role, “I am excited to join Genflow as the company is progressing to a new phase of development, with key data readouts expected in 2026, strengthened intellectual property, and a sharpened strategic focus on high-potential programs. I look forward to working with the talented team and board to advance these innovative gene therapies. This is an ideal moment to contribute my expertise and help drive Genflow forward, delivering long-term value for shareholders and patients.”

Genflow Biosciences, founded in 2020, is pioneering gene therapies designed to decelerate the aging process, aiming to extend healthy lifespans. The company’s lead compound, GF-1002, utilizes a centenarian variant of the SIRT6 gene. Genflow is currently conducting a 12-month proof-of-concept clinical trial for GF-1002 in aged dogs, with plans to explore its potential benefits in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH).

**Key Takeaways:**

* **Strategic Leadership:** Appointment of Gad Berdugo, a seasoned biotech executive with extensive experience in corporate development and RNA-LNP therapeutics, as Independent Non-Executive Chairman.
* **Pipeline Acceleration:** Berdugo’s expertise is expected to support the advancement of Genflow’s gene therapy programs and the evaluation of delivery technologies.
* **U.S. Market Focus:** The appointment aims to strengthen the company’s presence and engagement within the critical U.S. biotechnology ecosystem.
* **Near-Term Milestones:** Key data readouts are anticipated in 2026, presenting a pivotal period for program progression under new leadership.
* **Governance Continuity:** Tamara Joseph’s continued role on the board ensures stability and established governance practices.
* **Shareholder Alignment:** The chairman’s lack of current share ownership presents a point of observation for future shareholder value creation strategies.